Answers are grounded in this paper and cite their sources.
Review highlights the pathogenic role of the NLRP3 inflammasome in cardiac fibrosis, suggesting novel anti-inflammatory therapeutic strategies.
Cardiac fibrosis often has adverse cardiovascular effects, including heart failure, sudden death, and malignant arrhythmias. However, there is no targeted therapy for cardiac fibrosis. Inflammation is known to play a crucial role in the disorder, and the NLR pyrin domain-containing-3 (NLRP3) inflammasome is closely associated with innate immunity. Therefore, further understanding the pathophysiological role of the inflammasome in cardiac fibrosis may provide novel strategies for the prevention and treatment of the disorder. The aim of this review was to summarize the present knowledge of NLRP3 inflammasome-related mechanisms underlying cardiac fibrosis and to suggest potential targeted therapy that could be used to treat the condition.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: